2026-09-24 8-K filing
8-K: Item 1.01 D1 -3.0% · +5d -4.5%
2026-09-08 Company
Novartis Phase 3 Failure Drags SRPT Lower; Analyst Calls Sell-off Overdone Novartis' DM1 drug missed primary endpoint, raising read-through concerns for SRPT's similar program; Mizuho reiterates Outperform
D1 -6.9% · +5d -1.1%
8 earlier events › 2026-08-06 Company
New CEO Severino on First Call Notes Exondys Approval 10th Anniversary Analyst asks about potential separation of DMD business from gene therapy
D1 +5.3% · +5d +9.8%
2026-07-22 → 08-06 Earnings Bear
Sarepta Q2: Revenue beats estimates but down 34% YoY Results released; revenue and EPS beat estimates, but lower ELEVIDYS sales weighed on total revenue.
D1 -2.4% · +5d -1.8%
› 2 waves of this story2026-07-22 Results due after market close; investors eye financials amid DMD therapy competition.2026-08-06 Results released; revenue and EPS beat estimates, but lower ELEVIDYS sales weighed on total revenue.2026-08-06 Earnings
SRPT Q2 Revenue $401M Down 34% YoY, EPS $0.64 Beat, FY26 Guidance Lowered ELEVIDYS sales weak, FY26 revenue guidance cut to $1.2-1.3B, expense guidance tightened
D1 +5.3% · +5d +9.8%
› 3 waves of this story2026-08-06 Revenue decline driven by lower ELEVIDYS sales, yet EPS beat Zacks consensus2026-08-06 Company narrowed FY26 product revenue outlook to $1.2-1.3B and tightened expense guidance2026-08-06 ELEVIDYS sales weak, FY26 revenue guidance cut to $1.2-1.3B, expense guidance tightened2026-08-05 8-K filing
8-K: Item 2.02, Item 9.01 D1 -2.8% · +5d +15.4%
2026-08-05 Earnings
Earnings report D1 -2.8% · +5d +15.4%
2026-07-27 8-K filing
8-K: Item 5.02, Item 7.01, Item 9.01 D1 +1.3% · +5d -0.1%
2026-07-09 Analyst
Wolfe Research upgrades to Outperform D1 +1.5% · +5d -16.0%
2026-06-30 Regulation Bull
FDA Accepts Sarepta's sNDAs to Convert Two DMD Drugs to Traditional Approval FDA accepted sNDAs for AMONDYS 45 and VYONDYS 53 to convert from accelerated to traditional approval; PDUFA date Feb 28, 2027.
D1 +5.6% · +5d +12.5%
by direction · sourced
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
be the first
🙂 Post
Facts and opinions separated · All items sourced · Not investment advice
